Business Overview / Sources of Revenue

Aurinia Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases with high unmet medical needs.[1][2] The company's primary revenue driver is **LUPKYNIS (voclosporin)**, an oral therapy for treating adult patients with active lupus nephritis, which generated $66.6M in net product sales during Q2 2025.[1] This represents approximately 95% of the company's total Q2 revenue of $70M.[1]

Beyond LUPKYNIS, Aurinia is developing **AUR200**, a dual inhibitor of B cell activating factor and proliferation inducing ligand for potential treatment of various autoimmune diseases, which is currently in clinical trials.[1][2] The company maintains a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd.[1]

As of the trailing twelve months, Aurinia reported total revenues of approximately $265.81M with a net profit margin of 29.28%, demonstrating strong profitability driven primarily by LUPKYNIS commercialization.[2]

Revenue Growth Potential and Recurrence

Aurinia Pharmaceuticals generates recurring revenue primarily through LUPKYNIS (voclosporin), its FDA-approved oral therapy for lupus nephritis, which represents a stable, ongoing revenue stream from a chronic disease treatment.[5] This therapeutic focus on autoimmune diseases with high unmet medical needs supports consistent patient demand and recurring sales.

Revenue growth potential appears strong over the next 5+ years. The company demonstrated 23% revenue growth for the first half of 2025 and 17% growth for the nine-month period ending September 30, 2025.[4][6] Analyst estimates project sales growth of 10.03% for 2025 and 24.64% for 2026.[3] Additionally, Aurinia is developing aritinercept, a dual BAFF/APRIL inhibitor for autoimmune diseases, which could provide significant future growth drivers.[5] Historical data shows the company has experienced substantial earnings surprises, with a 200% average surprise rate across recent quarters,[3] suggesting strong operational momentum. However, growth rates may moderate from historical peaks, with current estimates indicating mid-teen to low-twenties percentage growth through 2026.

Economic Moat Factors

Aurinia Pharmaceuticals possesses several meaningful economic moat characteristics, though with notable limitations[1].

**Competitive Advantages:**

The company benefits from **patent protection and regulatory exclusivity** for LUPKYNIS, its flagship lupus nephritis treatment, creating a period of market dominance[1]. Additionally, Aurinia has developed **proprietary technology** in its unique formulation and targeted drug delivery, providing differentiation[1]. The company maintains an **established sales and marketing infrastructure** supporting commercialization[1].

**Moat Limitations:**

However, the moat remains relatively narrow. Aurinia faces **high dependence on a single product**—LUPKYNIS accounts for the vast majority of revenue[1]. The moat is primarily time-limited, relying on patent expiration rather than structural barriers like brand power or switching costs typical of broader moats[1]. While aritinercept is in development, it faces execution risk[1].

**Conclusion:**

Aurinia possesses a **temporary, patent-driven moat** rather than a durable one. Success depends heavily on LUPKYNIS market penetration and aritinercept's development trajectory.

Leadership

Peter Greenleaf serves as President and CEO of Aurinia Pharmaceuticals, a position he has held since 2019, giving him approximately 6.5 years of tenure.[1][5] He is not a founder but was brought in from external leadership roles, including previous positions at MedImmune (now AstraZeneca) and BioDelivery Sciences International.[1] Greenleaf owns 0.51% of the company, worth approximately $7.94 million, with total compensation of $6.42 million annually.[5] The management team is seasoned, with an average tenure of 5.5 years, including Chief Financial Officer Joe Miller and Chief Operating Officer Max Donley.[1][5] Key additions include Dr. Volker Knappertz as Executive Vice President of R&D.[6]

Financial Health

Aurinia Pharmaceuticals demonstrates solid financial health with a **flawless balance sheet and proven track record**.[2] The company generated **$119.6 million in free cash flow** recently, with analysts forecasting growth to $175.5 million by 2029.[2] This indicates a strong cash generation capability. The company reported **Q3 2025 revenue of $73.47 million** and **net income of $31.55 million**, showing profitability.[1] However, the search results do not provide specific information regarding the cash-to-debt ratio, free cash flow margin calculations, or share dilution/repurchase history. Based on available data, the company appears financially healthy with positive earnings and robust cash flow generation.

Last updated Dec 1, 2025